All In Biotech

Drug Trial Radar · NCT00509015

Mass-Drug Administration to Reduce Malaria Transmission

Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine

Last checked: Nov 19, 2026Latest source record: Aug 13, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,000

Planned (sponsor's estimate)

Start

Feb 2008

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Radboud University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kilimanjaro Christian Medical Centre, Tanzania; London School of Hygiene and Tropical Medicine
First posted
Jul 31, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'. Subsequently, MDA has received little attention until the introduction of artemisinin based combination therapy (ACT). The principle aim of MDA is to interrupt malaria transmission by clearing the population of sexual stage parasites, gametocytes, prior to the transmission season. Gametocytes are essential for propagation of the disease and elimination of gametocytes will result in a reduction in malaria transmission. As a consequence, a successful MDA will reduce the burden of disease in a population and is expected to have little influence on the development of protective immunity in areas of low transmission intensity. In Africa, only one large scale MDA study was conducted in the last 10 years. That study, conducted in The Gambia using sulphadoxine-pyrimethamine (SP) plus a single dose of artesunate (AS), failed to show a significant impact of MDA on malaria transmission. Possible reasons for this failure are the limited impact of the drug regimen (a single dose of AS) on malaria transmission, the incomplete coverage, the relatively high transmission intensity in the area and the migration of individuals between villages. Here, we propose to conduct an MDA study in an area of very low malaria transmission intensity in Tanzania. We use the highly active drug combination SP+AS (3 days) followed by a single dose of primaquine..

Conditions

  • Malaria, Falciparum

Interventions

  • Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)Drug

    500mg S\&25mg P/20 kg, 1 day, single dose

  • Artesunate (day 1,2,3: 4 mg/kg)Drug

    4 mg/kg, daily single dose over three days

  • Primaquine-base (day 3: 0.75 mg/kg)Drug

    single dose at 0.75 mg/kg on day 3

  • placebo tabletsDrug

    3 days of lactose tablets (160mg) albochin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. malaria morbidity by active and passive case detection.Time frame: during the entire study period
  2. asexual parasite prevalence and density by microscopy, rapid diagnostic test and molecular QT-NASBATime frame: monthly during the entire study period
  3. gametocyte prevalence and density by QT-NASBA and microscopyTime frame: monthly during the entire study period
  4. transmission intensity quantified by entomologic inoculation rateTime frame: continuously during the study period
  5. human infectious reservoirTime frame: prior to the intervention and several months after the intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kilimanjaro Christian Medical Centre

    Moshi, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.